{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:03:42Z","timestamp":1791241422787,"version":"4.1.0"},"reference-count":13,"publisher":"BMJ","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pathol"],"published-print":{"date-parts":[[1994,5]]},"abstract":"<jats:p>AIMS--To study the expression and importance (if any) of p53 protein in gall bladder carcinoma and its precursor lesions. METHODS--Immunohistochemical staining was performed on formalin fixed, paraffin wax embedded histological sections with an anti-human p53 monoclonal antibody (DO-7; Dako Corporation M7001) (24 carcinomas, one adenocarcinoma in situ, six dysplasias, three adenomas and four cases of chronic cholecystitis). Invasive, in situ, and dysplastic areas as well as normal-looking epithelium were sought. Nuclear staining was assessed according to intensity and extent of positive cells. Both variables were graded on a scale of 1-3 and aggregate p53 scores were obtained (range: 0, 2-6). Only p53 scores of &gt; or = 3 were regarded as significant. RESULTS--Clinically important amounts of p53 were expressed in 92% of invasive carcinomas, 86% of carcinoma in situ, and 28% of dysplastic areas. None of the adenomas contained clinically important amounts of p53. Normal epithelium, present in all the cases, did not express p53 except in one case of moderately differentiated adenocarcinoma (p53 score 3). In general, there was no difference in the prevalence of p53 protein expression between dysplasias associated with, and those unassociated with invasive disease. There was a tendency for higher grade carcinomas to express more p53 protein. CONCLUSIONS--The distribution of p53 protein in invasive carcinomas and the adjacent dysplastic and preinvasive lesions suggests that it is more commonly expressed than previously thought. The fact that p53 protein is also expressed in cases of dysplasia and carcinoma in situ unassociated with invasive malignancy lends further support to the contention that p53 gene mutations may have a role in the pathogenesis of gall bladder cancer. Expression of p53 protein may possibly be an indication of likely disease progression from dysplasia, to carcinoma in situ, to invasive disease.<\/jats:p>","DOI":"10.1136\/jcp.47.5.453","type":"journal-article","created":{"date-parts":[[2007,6,9]],"date-time":"2007-06-09T00:50:46Z","timestamp":1181350246000},"page":"453-456","source":"Crossref","is-referenced-by-count":66,"title":["Clinical importance of p53 protein in gall bladder carcinoma and its precursor lesions."],"prefix":"10.1136","volume":"47","author":[{"given":"A","family":"Wee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G C","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[1994,5,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/351453a0","article-title":"The p53 tumor suppressor gene","volume":"351","author":"Levine, A.J.; Momad, J.; Finlay, C.A.","year":"1991","unstructured":"Levine AJ, Momad J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.","journal-title":"Nature"},{"key":"ref_2","first-page":"5","article-title":"Mutant p53-the commonest genetic abnormality in human cancer?","volume":"162","author":"Hams, A.L.","year":"1990","unstructured":"Hams AL. Mutant p53-the commonest genetic abnormality in human cancer? I Clin Pathol 1990;162:5-6.","journal-title":"I Clin Pathol"},{"key":"ref_3","first-page":"749","article-title":"Altered expression of wildtype p53 tumor suppressor gene during murine epithelial cell transformation","volume":"52","author":"Han, K.; Kulesz-Martin, M.F.","year":"1992","unstructured":"Han K, Kulesz-Martin MF. Altered expression of wildtype p53 tumor suppressor gene during murine epithelial cell transformation. Cancer Res 1992;52:749-53.","journal-title":"Cancer Res"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/path.1711690106","article-title":"Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies","volume":"169","author":"Bartek, J.; Bartkova, J.; Lukas, J.; Staskova, Z.; Vojtesek, B.; Lane, D.P.","year":"1993","unstructured":"Bartek J, Bartkova J, Lukas J, Staskova Z, Vojtesek B, Lane DP. Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol 1993;169:27-34.","journal-title":"J Pathol"},{"key":"ref_5","first-page":"145","article-title":"Widespread p53 overexpression in human malignant tumors","volume":"140","year":"1992","unstructured":"Porter PL, Gown AM, Kramp SG, Coltrera MD. Widespread p53 overexpression in human malignant tumors. Am I Pathol 1992;140:145-53.","journal-title":"Am I Pathol"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/path.1711700111","article-title":"p53 and c-erb B-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder","volume":"170","author":"Kamel, D.; Paakko, P.; Nuorva, K.; Viahkangas, K.; Soini, Y.","year":"1993","unstructured":"Kamel D, Paakko P, Nuorva K, Viahkangas K, Soini Y. p53 and c-erb B-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. Y Pathol 1993;170:67-72.","journal-title":"Y Pathol"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0092-8674(89)90045-7","article-title":"The p53 protooncogene can act as a suppressor of transformation","volume":"57","author":"Finlay, C.A.; Hinds, P.W.; Levine, A.J.","year":"1989","unstructured":"Finlay CA, Hinds PW, Levine AJ. The p53 protooncogene can act as a suppressor of transformation. Cell 1989; 57:1083-93.","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/1097-0142(19800301)45:5<919::AID-CNCR2820450514>3.0.CO;2-4","article-title":"The precursor lesions of invasive gall-bladder carcinoma: Hyperplasia, atypical hyperplasia and carcinoma in situ","volume":"45","author":"Albores-Saavedra, J.; Alcintara-Vazquez, A.; Cruz Ortiz, H.; Herrera-Goepfert, R.","year":"1980","unstructured":"Albores-Saavedra J, Alcintara-Vazquez A, Cruz Ortiz H, Herrera-Goepfert R. The precursor lesions of invasive gall-bladder carcinoma: Hyperplasia, atypical hyperplasia and carcinoma in situ. Cancer 1980;45:919-27.","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.1905840","article-title":"p53 mutations in human cancers","volume":"253","author":"Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C.","year":"1991","unstructured":"Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991;253:49-53.","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/316158a0","article-title":"Overproduction of p53 antigen makes established cells highly tumorigenic","volume":"316","author":"Eliyahu, D.; Michalovitz, D.; Oren, M.","year":"1985","unstructured":"Eliyahu D, Michalovitz D, Oren M. Overproduction of p53 antigen makes established cells highly tumorigenic. Nature 1985;316: 158-62.","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF01611179","article-title":"Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas","volume":"421","author":"Soini, Y.; Paikko, P.; Nuorva, K.; Kamel, D.; Lane, D.P.; Vihakangas, K.","year":"1992","unstructured":"Soini Y, Paikko P, Nuorva K, Kamel D, Lane DP, Vihakangas K. Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas. Virchows Arch (PatholAnat) 1992;421:223-8.","journal-title":"Virchows Arch (PatholAnat)"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/bjc.1991.74","article-title":"p53 in colorectal cancer: clinicopathological correlation and prognostic significance","volume":"63","author":"Scott, N.; Sagar, P.; Stewart, J.; Blair, G.E.; Dixon, M.F.; Quirke, P.","year":"1991","unstructured":"Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. BrJ7 Cancer 1991;63:317-9.","journal-title":"BrJ7 Cancer"},{"key":"ref_13","first-page":"329","article-title":"p53 in tumour pathology: can we trust immunocytochemistry?","volume-title":"I Pathol","volume":"166","author":"Wynford-Thomas, D.","year":"1992","unstructured":"Wynford-Thomas D. p53 in tumour pathology: can we trust immunocytochemistry? I Pathol 1992;166:329-30."}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp.47.5.453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:38:51Z","timestamp":1765600731000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp.47.5.453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,5]]},"references-count":13,"journal-issue":{"issue":"5","published-online":{"date-parts":[[1994,5,1]]},"published-print":{"date-parts":[[1994,5]]}},"alternative-id":["10.1136\/jcp.47.5.453"],"URL":"https:\/\/doi.org\/10.1136\/jcp.47.5.453","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,5]]}}}